New pyridobenzoxazepine derivatives derived from 5-(4-methylpiperazin-1-yl) -8-chloro-pyrido[2,3-b ][1,5]benzoxazepine (JL13): Chemical synthesis and pharmacological evaluation

Journal of Medicinal Chemistry

Volumn 55, Issue 4, 2012, Pages 1572-1582

  Liégeois, Jean François ^a   Deville, Marine ^a   Dilly, Sébastien ^a   Lamy, Cédric ^a   Mangin, Floriane ^a   Résimont, Mélissa ^a   Tarazi, Frank I ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 METHYLPIPERAZIN 1 YL) 8 CHLOROPYRIDO[2,3 B][1,5]BENZOXAZEPINE; ALPHA ADRENERGIC RECEPTOR; AZEPINE DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; PYRIDOBENZOXAZEPINE DERIVATIVE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN CORTEX; CAUDATE NUCLEUS; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HIPPOCAMPUS; IN VITRO STUDY; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; MALE; MODELS, MOLECULAR; ORGAN SPECIFICITY; OXAZEPINES; PIPERAZINES; PYRIDINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84857410638     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm2013419     Document Type: Article

References (58)

1. 2 pKi values J. Pharmacol. Exp. Ther. 1989, 251, 238-246
2. Liégeois, J.-F.; Eyrolles, L.; Bruhwyler, J.; Delarge, J. Dopamine D4 receptors: A new opportunity for research on schizophrenia Curr. Med. Chem. 1998, 5, 77-100 (Pubitemid 28183851)
3. Tarazi, F. I.; Zhang, K.; Baldessarini, R. J. Dopamine D4 receptors: Beyond schizophrenia J. Recept. Signal Transduction Res. 2004, 24, 131-147
4. Enguehard-Gueiffier, C.; Gueiffier, A. Recent progress in medicinal chemistry of D4 agonists Curr. Med. Chem. 2006, 13, 2981-2993 (Pubitemid 44509702)
5. Rondou, P.; Haegeman, G.; Van Craenenbroeck, K. The dopamine D4 receptor: Biochemical and signalling properties Cell. Mol. Life Sci. 2010, 67, 1971-1986
6. Löber, S.; Hübner, H.; Tschammer, N.; Gmeiner, P. Recent advances in the search for D3- and D4-selective drugs: Probes, models and candidates Trends Pharmacol. Sci. 2011, 32, 148-157
7. Niswender, C. M.; Conn, P. J. Metabotropic glutamate receptors: Physiology, pharmacology, and disease Annu. Rev. Pharmacol. Toxicol. 2010, 50, 295-322
8. Krystal, J. H.; Mathew, S. J.; D'Souza, D. C.; Garakani, A.; Gunduz-Bruce, H.; Charney, D. S. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists CNS Drugs 2010, 24, 669-693
9. Roth, B. L.; Sheffler, D. L.; Kroeze, W. K. Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia Nat. Rev. Drug Discovery 2004, 3, 353-259
10. Chung, Y.-C.; Li, Z.; Dai, J.; Meltzer, H. Y.; Ichikawa, J. Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: Role of 5-HT1A receptor agonism Brain Res. 2004, 1023, 54-63 (Pubitemid 39195334)
11. 1A receptor activation: A possible mechanism of atypical antipsychotic-induced cortical dopamine release J. Neurochem. 2001, 76, 1521-1531 (Pubitemid 32198256)
12. 1A receptor agonism Brain Res. 2002, 956, 349-357 (Pubitemid 35351402)
13. Roth, B. L.; Hanizavareh, S. M.; Blum, A. E. Serotonin receptors represent highly favourable molecular targets for cognitive enhancement in schizophrenia and other disorders Psychopharmacology (Berlin) 2004, 174, 17-24 (Pubitemid 38925086)
14. Hertel, P.; Fagerquist, M. V.; Svensson, T. H. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade Science 1999, 286, 105-107 (Pubitemid 29484485)
15. Jacobson, S. M.; Prus, A. J. Evaluation of the effects of a2-adrenoceptor antagonism with the D2 receptor antagonist raclopride on conditioned avoidance responding in rats Behav. Pharmacol. 2010, 21, 654-659
16. Invernizzi, R. W.; Garavaglia, C.; Samanin, R. The alpha 2-adrenoceptor antagonist idazoxan reverses catalepsy induced by haloperidol in rats independent of striatal dopamine release: role of serotonergic mechanisms Neuropsychopharmacology 2003, 28, 872-879
17. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm J. Med. Chem. 2005, 48, 6523-6543 (Pubitemid 41504710)
18. Marino, M. J.; Knutsen, L. J. S.; Williams, M. Emerging opportunities for antipsychotic drug discovery in the postgenomic era J. Med. Chem. 2008, 51, 1077-1107 (Pubitemid 351480372)
19. Ellenbroek, B. A.; Liégeois, J.-F. JL13, an atypical antipsychotic: A preclinical review CNS Drug Rev. 2003, 9, 41-57
20. Invernizzi, R. W.; Garavaglia, C.; Samanin, R. JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity, increases extracellular dopamine in the prefrontal cortex, but not in the striatum and the nucleus accumbens of rats Naunyn-Schmiedeberg's Arch. Pharmacol. 2000, 361, 298-302 (Pubitemid 30106342)
21. Ellenbroek, B. A.; Liégeois, J.-F.; Bruhwyler, J.; Cools, A. R. The effects of JL13, a pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models for schizophrenia J. Pharmacol. Exp. Ther. 2001, 298, 386-391 (Pubitemid 32574551)
22. Bruhwyler, J.; Liégeois, J.-F.; Bergman, J.; Carey, G.; Goudie, A.; Taylor, A.; Meltzer, H. Y.; Delarge, J.; Géczy, J. JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: A review of its behavioural properties Pharmacol. Res. 1997, 36, 255-264 (Pubitemid 27507581)
23. Casey, D. E.; Bruhwyler, J.; Delarge, J.; Géczy, J.; Liégeois, J.-F. The behavioral effects of acute and chronic JL13, a putative antipsychotic, in Cebus non-human primates Psychopharmacology 2001, 157, 228-235 (Pubitemid 32905563)
24. Moran-Gates, T.; Massari, C.; Graulich, A.; Liégeois, J.-F.; Tarazi, F. I. Long-term effects of novel atypical antipsychotic JL13 on dopamine and serotonin receptor subtypes J. Neurosci. Res. 2006, 84, 675-682 (Pubitemid 44196708)
25. Tarazi, F. I.; Moran-Gates, T.; Gardner, M.; Graulich, A.; Lamy, C.; Liégeois, J.-F. Long-term effects of JL13, a potential atypical antipsychotic, on ionotropic glutamate receptors J. Mol. Neurosci. 2007, 32, 192-198 (Pubitemid 47574967)
26. Liégeois, J.-F.; Mouithys-Mickalad, A.; Bruhwyler, J.; Delarge, J.; Petit, C.; Kauffmann, J.-M.; Lamy, M. JL13, a potential successor to clozapine is less sensitive to oxidative phenomenons Biochem. Biophys. Res. Commun. 1997, 238, 252-255 (Pubitemid 27453310)
27. Liégeois, J.-F.; Rogister, F.; Delarge, J.; Pincemail, J. Peroxidase-catalysed oxidation of different dibenzazepine derivatives Arch. Pharm. (Weinheim) 1995, 328, 109-112
28. Liégeois, J.-F.; Bruhwyler, J.; Petit, C.; Damas, J.; Delarge, J.; Géczy, J.; Kauffmann, J.-M.; Lamy, M.; Meltzer, H. Y.; Mouithys-Mickalad, A. Oxidation sensitivity may be a useful tool for the detection of the hematotoxic potential of newly developed molecules: Application to antipsychotic drugs Arch. Biochem. Biophys. 1999, 370, 126-137 (Pubitemid 29476959)
29. Dilly, S.; Liégeois, J.-F. The formation of nitrenium ion also influences binding of clozapine on rat D2 dopamine receptors: docking studies and in vitro binding assays J. Comput.-Aided Mol. Des. 2011, 25, 163-169
30. Liégeois, J.-F.; Rogister, F.; Bruhwyler, J.; Damas, J.; Nguyen, T. P.; Inarejos, M. O.; Chleide, E.; Mercier, M.; Delarge, J. Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: Synthesis and neurochemical study J. Med. Chem. 1994, 37, 519-525 (Pubitemid 24094833)
31. Liégeois, J.-F.; Bruhwyler, J.; Damas, J.; Nguyen, T. P.; Chleide, E.; Mercier, M.; Rogister, F.; Delarge, J. New pyridobenzodiazepine derivatives as potential antipsychotics: synthesis and neurochemical study J. Med. Chem. 1993, 36, 2107-2114 (Pubitemid 23241145)
32. 2A) binding J. Med. Chem. 2002, 45, 5136-5149 (Pubitemid 35278709)
33. Fryer, R. I.; Earley, J. V.; Field, G. F.; Zally, W.; Sternbach, L. H. A synthesis of amidines from cyclic amides J. Org. Chem. 1969, 34, 1143-1145
34. Goudie, A. J.; Cole, J. C.; Sumnall, H. R. Olanzapine and JL13 induce cross-tolerance to the clozapine discriminative stimulus in rats Behav. Pharmacol. 2007, 18, 9-17 (Pubitemid 46103279)
35. Capuano, B.; Crosby, I. T.; MacRobb, F. M.; Taylor, D. A.; Vom, A.; Blessing, W. W. JL13 has clozapine-like actions on thermoregulatory cutaneous blood flow in rats: involvement of serotonin 5-HT1A and 5-HT2A receptor mechanisms Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34, 136-142
36. Capuano, B.; Crosby, I. T.; Lloyd, E. J.; Neve, J. E.; Taylor, D. A. Aminimides as potential CNS acting agents. I. Design, synthesis, and receptor binding of 4′-aryl aminimide analogues of clozapine as prospective novel antipsychotics Aust. J. Chem. 2007, 60, 673-684 (Pubitemid 47389197)
37. Capuano, B.; Crosby, I. T.; Lloyd, E. J.; Taylor, D. A. Synthesis and preliminary pharmacological evaluation of 4′-arylalkyl analogues of clozapine. III. Replacement of the tricyclic nucleus with a bicyclic template Aust. J. Chem. 2007, 60, 928-933 (Pubitemid 350210622)
38. Capuano, B.; Crosby, I. T.; Lloyd, E. J.; Neve, J. E.; Taylor, D. A. Aminimides as potential CNS acting agents. II. Design, synthesis, and receptor binding of 4′-arylalkyl aminimide analogues of clozapine as prospective novel antipsychotics Aust. J. Chem. 2008, 60, 5-10
39. Capuano, B.; Crosby, I. T.; Lloyd, E. J.; Podloucka, A.; Taylor, D. A. Synthesis and preliminary pharmacological evaluation of 4′-arylalkyl analogues of clozapine. IV. The effects of aromaticity and isosteric replacement Aust. J. Chem. 2008, 60, 930-940
40. Li, Z.; Huang, M.; Ichikawa, J.; Dai, J.; Meltzer, H. Y. N-Desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors Neuropsychopharmacology 2005, 30, 1986-1995 (Pubitemid 43093499)
41. Prus, A. J.; Pehrson, A. L.; Philibin, S. D.; Wood, J. T.; Vunck, S. A.; Porter, J. H. The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic drug clozapine in rats Psychopharmacology (Berlin) 2009, 203, 295-301
42. Apiquian, R.; Ulloa, E.; Fresan, A.; Loyzaga, C.; Nicolini, H.; Kapur, S. Amoxapine shows atypical antipsychotic effects in paptients with schizophrenia: results from a prospective open-label study Schizophr. Res. 2003, 59, 35-39 (Pubitemid 35284491)
43. Jensen, N. H.; Rodriguiz, R. M.; Caron, M. G.; Wetsel, W. C.; Rothman, R. B.; Roth, B. L. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity Neuropsychopharmacology 2008, 33, 2303-2312
44. Shobo, M.; Kondo, Y.; Yamada, H.; Mihara, T.; Yamamoto, N.; Katsuoka, M.; Harada, K.; Ni, K.; Matsuoka, N. Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake J. Pharmacol. Exp. Ther. 2010, 333, 772-781
45. Lamy, C. Synthesis, evaluation and psychopharmacological evaluation of potential antipsychotics. Master Thesis in Pharmaceutical Sciences, University of Liège, 2005
46. Florijn, W. J.; Tarazi, F. I.; Creese, I. Dopamine receptor subtypes: Differential regulation after 8 months treatment with antipsychotic drugs J. Pharmacol. Exp. Ther. 2007, 280, 561-569
47. Tarazi, F. I.; Zhang, K.; Baldessarini, R. J. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions Psychopharmacology 2002, 161, 263-270 (Pubitemid 34591664)
48. Ho, B. Y.; Karschin, A.; Branchek, T.; Davidson, N.; Lester, H. A. The role of conserved aspartate and serine residues in ligand binding and in function of the 5-HT1A receptor: A site-directed mutation study Febs Lett. 1992, 312, 259-262
49. Strader, C. D.; Candelore, M. R.; Hill, W. S.; Sigal, I. S.; Dixon, R. A. F. Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor J. Biol. Chem. 1989, 264, 13572-13578 (Pubitemid 19198437)
50. Hibert, M. F.; Trumpp-Kallmeyer, S.; Bruinvels, A.; Hoflack, J. Three-dimensional models of neurotransmitter G-binding protein-coupled receptors Mol. Pharmacol. 1991, 40, 8-15
51. Trumpp-Kallmeyer, S.; Hoflack, J.; Bruinvels, A.; Hibert, M. F. Modeling of G-protein-coupled receptors: application to dopamine, adrenaline, serotonin, acetylcholine, and mammalian opsin receptors J. Med. Chem. 1992, 35, 3448-3462
52. Carelli, R. M. The nucleus accumbens and reward: Neurophysiological investigations in behaving animals Behav. Cogn. Neurosci. Rev. 2002, 1, 281-296
53. Tarazi, F. I.; Zhang, K.; Baldessarini, R. J. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment J. Pharmacol. Exp. Ther. 2001, 297, 711-717 (Pubitemid 32378004)
54. 1A receptors in ventral prefrontal cortex in schizophrenia Biol. Psychiatry 1996, 39, 919-928
55. Greene, W. H. Econometric Analysis, 4th ed.; Prentice Hall: Upper Saddle River, NJ, 2000; pp 462-465.
56. Winer, B. J.; Brown, D. R.; Michels, K. M. Statistical Principles in Experimental Drug Design; 3rd ed.; McGraw Hill: New York, 1991, pp 165-166.
57. 1A agonism potential of substituted-piperazine-ethyl-amide derivatives is conserved in the hexyl homologues: Molecular modelling and pharmacological evaluation J. Chem. Inf. Model. 2011, 51, 2961-2966
58. Hilal, S. H.; El-Shabrawy, Y.; Carreira, L. A.; Karickhoff, S. W.; Toubar, S. S.; Rizk, M. Estimation of the ionization pK(a) of pharmaceutical substances using the computer program Sparc Talanta 1996, 43, 607-619 (Pubitemid 126657096)